Upside case
Bull case
$29+60.4%
KVUE would need investors to value it at roughly 24x earnings — about 9x more generous than today's 15x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
Analysis OverviewHoldUpdated Jun 18, 2026
Kenvue Inc. (KVUE) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Hold
Covering
14
analysts
4 bullish · 0 bearish · 14 covering KVUE
Strong Buy
0
Buy
4
Hold
10
Sell
0
Strong Sell
0
Consensus Target
$18
+0.7% vs today
Scenario Range
$14 – $29
Model bear to bull value window
Coverage
14
Published analyst ratings
Valuation Context
15.2x
Forward P/E · Market cap $34.8B
KVUE price targets
Three scenarios for where KVUE stock could go
Current
~$18
Confidence
42 / 100
Updated
Jun 18, 2026
Where we are now
Current · $18
Bear
$14
Base
$22
Bull
$29
Market caseClosest to today
Base case
$22+21.7%
At 18x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
Stress case
Bear case
$14-23.3%
If investor confidence fades or macro conditions deteriorate, a 4x multiple contraction could push KVUE down roughly 23% from where it trades now.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Kenvue Inc.
KVUE · NYSEConsumer DefensiveHousehold & Personal ProductsDecember year-end
Kenvue is a consumer health company that sells over-the-counter medications, skincare products, and essential health items through well-known brands like Tylenol, Neutrogena, and Band-Aid. It generates revenue primarily from three segments: Self Care (pain relief, allergy, digestive health), Skin Health and Beauty (skincare, haircare), and Essential Health (oral care, baby care, wound care) — each contributing roughly one-third of sales. The company's key advantage is its portfolio of trusted, household-name brands with decades of consumer loyalty and recognition.
Market Cap
$34.8B
Revenue TTM
$15.3B
Net Income TTM
$1.6B
Net Margin
10.6%
KVUE Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
92%Exceptional
12 quarters tracked
Revenue Beat Rate
58%Exceptional
vs consensus estimates
Avg EPS Surprise
+9.3%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 4 of 4Q3 2025
EPS
$0.29/$0.28
Revenue
$3.8B/$3.9B
Q4 2025
EPS
$0.28/$0.26
Revenue
$3.8B/$3.8B
Q1 2026
EPS
$0.27/$0.22
Revenue
$3.8B/$3.7B
Q2 2026
EPS
$0.32/$0.26
Revenue
$3.9B/$3.8B
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $0.29/$0.28 | +2.9% | $3.8B/$3.9B | -0.4% |
| Q4 2025 | $0.28/$0.26 | +7.6% | $3.8B/$3.8B | -1.5% |
| Q1 2026 | $0.27/$0.22 | +21.2% | $3.8B/$3.7B | +2.6% |
| Q2 2026 | $0.32/$0.26 | +22.1% | $3.9B/$3.8B | +1.7% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$15.4B
+0.6% YoY
FY2
$15.6B
+1.5% YoY
EPS Outlook
FY1
$0.91
+8.2% YoY
FY2
$0.92
+1.2% YoY
Trailing FCF (TTM)$1.8B
FCF Margin: 11.9%
Next Earnings
August 6, 2026
Expected EPS
$0.32
Expected Revenue
$4.0B
KVUE beat EPS estimates in 4 of 4 tracked quarters. A perfect track record raises the bar for the upcoming report.
KVUE Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $15.1B
Product Mix
Latest annual revenue by segment or product family
Self Care
42.2%
-2.3% YoY
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
North America
48.0%
-4.2% YoY
Tap, hover, or focus a slice to inspect segment detail.
Self Care is the largest disclosed segment at 42.2% of FY 2025 revenue, down 2.3% YoY.
North America is the largest reported region at 48.0%, down 4.2% YoY.
KVUE Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Cheap versus peers
Fair value est. $23 — implies +29.3% from today's price.
Upside to Fair Value
29.3%
potential upside
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
KVUE
23.8x
vs
S&P 500
24.4x
In line with benchmark
vs Consumer Defensive Trailing P/E
KVUE
23.8x
vs
Consumer Defensive
18.9x
+26% premium
vs KVUE 5Y Avg P/E
Today
23.8x
vs
5Y Average
29.1x
18% discount
Forward PE
15.2x
S&P 500
18.8x
-19%
Consumer Defensive
14.2x
+7%
5Y Avg
—
—
Trailing PE
23.8x
S&P 500
24.4x
-2%
Consumer Defensive
18.9x
+26%
5Y Avg
29.1x
-18%
PEG Ratio
—
S&P 500
1.66x
—
Consumer Defensive
1.92x
—
5Y Avg
—
—
EV/EBITDA
13.0x
S&P 500
15.2x
-15%
Consumer Defensive
11.1x
+17%
5Y Avg
15.9x
-19%
Price/FCF
20.2x
S&P 500
20.7x
-2%
Consumer Defensive
15.3x
+32%
5Y Avg
21.8x
-7%
Price/Sales
2.3x
S&P 500
3.1x
-26%
Consumer Defensive
0.9x
+161%
5Y Avg
2.5x
-8%
Dividend Yield
4.53%
S&P 500
1.91%
+137%
Consumer Defensive
3.06%
+48%
5Y Avg
4.26%
+6%
| Metric | KVUE | S&P 500 | Consumer Defensive | 5Y Avg KVUE |
|---|---|---|---|---|
| Forward PE | 15.2x | 18.8x-19% | 14.2x | — |
| Trailing PE | 23.8x | 24.4x | 18.9x+26% | 29.1x-18% |
| PEG Ratio | — | 1.66x | 1.92x | — |
| EV/EBITDA | 13.0x | 15.2x-15% | 11.1x+17% | 15.9x-19% |
| Price/FCF | 20.2x | 20.7x | 15.3x+32% | 21.8x |
| Price/Sales | 2.3x | 3.1x-26% | 0.9x+161% | 2.5x |
| Dividend Yield | 4.53% | 1.91% | 3.06% | 4.26% |
KVUE trades above S&P 500 benchmarks on 0 of 5 measured multiples — appears modestly priced relative to the S&P 500 on most measures.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolKVUE Financial Health
Verdict
Strong
KVUE generates $1.8B in free cash flow at a 11.9% margin — 11.4% ROIC signals a durable competitive advantage · returns 5.1% of market cap to shareholders annually.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$15.3B
Revenue Growth
TTM vs prior year
-0.1%
Gross Margin
Gross profit as a share of revenue
58.4%
Operating Margin
Operating income divided by revenue
19.6%
Net Margin
Net income divided by revenue
10.6%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$0.84
Free Cash Flow (TTM)
Cash generation after capex
$1.8B
FCF Margin
FCF as share of revenue — the primary cash quality signal
11.9%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
11.4%
ROA
Return on assets, trailing twelve months
6.0%
Cash & Equivalents
Liquid assets on the balance sheet
$1.1B
Net Debt
Total debt minus cash
$7.5B
Debt Serviceability
Net debt as a multiple of annual free cash flow
4.1× FCF
~4.1 years to full repayment at current FCF run-rate
ROE
Return on equity, trailing twelve months
15.2%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
5.1%
Dividend
4.5%
Buyback
0.6%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$197M
Dividend / Share
Annualized trailing dividend per share
$0.82
Payout Ratio
Share of earnings distributed as dividends
107.6%
Shares Outstanding
Declining as buybacks retire shares
1.9B
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageKVUE Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated June 18, 2026
High Risk
Finance & Corporate Risks
Kenvue, Inc. disclosed 68 risk factors in its most recent earnings report, with the majority concentrated in the 'Finance & Corporate' category, indicating significant financial and operational vulnerabilities.
Medium
Market Competition
As the world's largest pure-play consumer health company, Kenvue faces intense competition in the consumer health and personal care markets, which could pressure margins and market share.
Lower
Investor Sentiment
The stock's performance may be influenced by investor sentiment and market conditions, as highlighted by the need for analysis of price targets and short interest.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why KVUE Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated June 18, 2026
Strong valuation metrics
KVUE's trailing and forward P/E ratios of 24.93 and 17.01 respectively indicate attractive valuation potential.
Bullish analyst coverage
Multiple bullish theses on Kenvue Inc. have been published by analysts like Danny Green and ZeeContrarian1, highlighting positive sentiment.
Pre-acquisition potential
A bullish thesis was published before KVUE's acquisition, suggesting underlying strength and growth prospects.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
KVUE Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$18.12
52W Range Position
46%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$14.02
+29.2% from the low
52-Week High
$22.87
-20.8% from the high
1 Month
+5.47%
3 Month
+3.48%
YTD
+4.6%
1 Year
-15.2%
3Y CAGR
-11.4%
5Y CAGR
-7.6%
10Y CAGR
-3.9%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
KVUE vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
15.2x
vs 23.5x median
-35% below peer median
Revenue Growth
+0.6%
vs +1.3% median
-50% below peer median
Net Margin
10.6%
vs 10.5% median
+1% above peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
KVU KVUE Kenvue Inc. | $34.8B | 15.2x | +0.6% | 10.6% | Hold | +0.7% |
PG PG The Procter & Gamble Company | $351.4B | 21.8x | +1.3% | 14.7% | Buy | +5.7% |
CL CL Colgate-Palmolive Company | $71.8B | 23.5x | +4.1% | 10.5% | Hold | +7.3% |
CHD CHD Church & Dwight Co., Inc. | $22.7B | 25.5x | +4.3% | 11.8% | Buy | +9.8% |
EL EL The Estée Lauder Companies Inc. | $30.6B | 34.9x | +0.3% | -1.7% | Hold | +20.4% |
PRG PRGO Perrigo Company plc | $1.4B | 4.8x | +1.2% | -43.5% | Hold | +253.2% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
KVUE Dividend and Capital Return
KVUE returns 5.1% total yield, led by a 4.53% dividend, raised 56 consecutive years. Buybacks add another 0.6%.
Dividend SustainableFCF Stretched
Total Shareholder Yield
5.1%
Dividend + buyback return per year
Buyback Yield
0.6%
Dividend Yield
4.53%
Payout Ratio
1.1%
How KVUE Splits Its Return
Div 4.53%
Dividend 4.53%Buybacks 0.6%
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$0.82
Growth Streak
Consecutive years of dividend increases
56Y
3Y Div CAGR
—
5Y Div CAGR
—
Ex-Dividend Date
—
Payment Cadence
Quarterly
4 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$197M
Estimated Shares Retired
11M
Approx. Share Reduction
0.6%
Shares Outstanding
Current diluted share count from the screening snapshot
1.9B
At 0.6%/year, buybacks mechanically lift EPS even with flat earnings — each remaining share represents a slightly larger piece of the company.
| Year | Div / Share | YoY Grw | BB Yield | Total Yield |
|---|---|---|---|---|
| 2026 | $0.41 | — | — | — |
| 2025 | $0.82 | +1.9% | 0.6% | 5.4% |
| 2024 | $0.81 | +102.5% | 0.6% | 4.3% |
| 2023 | $0.40 | — | 0.0% | 35.3% |
FAQ
7 questionsKVUE Investor Questions
Common questions answered from live analyst data and company financials.
01Is Kenvue Inc. (KVUE) stock a buy or sell in 2026?
Kenvue Inc. (KVUE) is rated Hold by Wall Street analysts as of 2026. Of 14 analysts covering the stock, 4 rate it Buy or Strong Buy, 10 rate it Hold, and 0 rate it Sell or Strong Sell. The consensus 12-month price target is $18, implying +0.7% from the current price of $18. The bear case scenario is $14 and the bull case is $29.
02What is the KVUE stock price target for 2026?
The Wall Street consensus price target for KVUE is $18 based on 14 analyst estimates. The high-end target is $19 (+4.9% from today), and the low-end target is $18 (-0.7%). The base case model target is $22.
03Is Kenvue Inc. (KVUE) stock overvalued in 2026?
KVUE trades at 15.2x times forward earnings. The stock's valuation is broadly in line with the broader market. Based on current multiples versus the peer group, the relative model signals cheap versus peers. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
04What are the main risks for Kenvue Inc. (KVUE) stock in 2026?
The primary risks for KVUE in 2026 are: (1) Finance & Corporate Risks — Kenvue, Inc. (2) Market Competition — As the world's largest pure-play consumer health company, Kenvue faces intense competition in the consumer health and personal care markets, which could pressure margins and market share. (3) Investor Sentiment — The stock's performance may be influenced by investor sentiment and market conditions, as highlighted by the need for analysis of price targets and short interest. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is Kenvue Inc.'s revenue and earnings forecast?
Analyst consensus estimates KVUE will report consensus revenue of $15.4B (+0.6% year-over-year) and EPS of $0.91 (+8.2% year-over-year) for the upcoming fiscal year. The following year, analysts project $15.6B in revenue.
06When does Kenvue Inc. (KVUE) report its next earnings?
Kenvue Inc. is expected to report its next earnings on approximately 2026-08-06. Consensus expects EPS of $0.32 and revenue of $4.0B. Over recent quarters, KVUE has beaten EPS estimates 92% of the time.
07How much free cash flow does Kenvue Inc. generate?
Kenvue Inc. (KVUE) generated $1.8B in free cash flow over the trailing twelve months — a free cash flow margin of 11.9%. KVUE returns capital to shareholders through dividends (4.5% yield) and share repurchases ($197M TTM).